Vascular Parkinsonism Clinical Trial
— rTMSOfficial title:
Effect of Repetitive Transcranial Magnetic Stimulation in Vascular Parkinsonism
Vascular parkinsonism (VP), parkinsonism resulting from ischemic cerebrovascular disease, was
suggested in 1929. The main features are wide-based gait, postural instability, and falls,
which make patients with VP frustrated. Currently, the treatment is challenging.
Transcranial magnetic stiumation is a noninvasive procedure using electromagnetic induction
to stimulate brain, and repetitive transcranial magnetic stiumation (rTMS) can selectively
change brain activity to enhance desired effects. The aim of this study is to explore the
therapeutic effect of rTMS for the VP.
Status | Not yet recruiting |
Enrollment | 32 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Vascular parkinsonism - age 18 and older Exclusion Criteria: - pregnant or any, other medical, surgical, neurological or psychiatric conditions - other restrictions which prevent you from undergoing TMS recording, such as; surgically or traumatically implanted foreign bodies such as a pacemaker, an implanted medication pump, a metal plate in the skull, or metal inside the skull or eyes (other than dental appliances or fillings), and/ or heart/cardiac lines - any past or current history of seizure disorder or epilepsy - unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Inje university, Busan Paik Hospital | Busan |
Lead Sponsor | Collaborator |
---|---|
Inje University | Dongtan Sacred Heart Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Unified Parkinson's Disease Rating Scale (UPDRS) part III-motor part (Number 18 ~31 of UPDRS) | Motor functions will be checked using UPDRS. Each item of the motor part ranges from 0 to 4 (0 means normal, 4 means worst condition). Total sum will be calculated. | 2 days | |
Secondary | Finger tapping test with right hand | Finger tapping test with right hand, as quickly as possible for 15 second. The total number of taps will be calculated. The test will be twice with one minute interval. After the test performed twice, the average of the tests will be used. | 2 days | |
Secondary | The total number of steps during the stand-walk-sit (SWS) test | SWS test is Standing up, making a 9 m round trip, and sitting down as quickly as possible. The number of steps will be recorded. | 2 days | |
Secondary | The completion time during the SWS test | The completion time will be recorded. | 2 days | |
Secondary | Freezing episodes of gait trajectory | The number of freezing episodes during rapid full turns and dual task | 2 days | |
Secondary | Patient and Clinical Global Impression Scale | 7-point scale that requires the patient (or clinician) to rate the response of the interventions. The rating will be numbered (1: very much improved; 2: much improved; 3: minimally improved; 4: no changes; 5: minimally worse; 6: much worse; 7: very much worse). | 2 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04308135 -
Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease
|
||
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Completed |
NCT02195154 -
18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism
|
Phase 2 | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Not yet recruiting |
NCT06174948 -
The Use of the CUE1 in People With Parkinson's Disease and Related Disorders
|
N/A | |
Completed |
NCT04925622 -
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
|
||
Terminated |
NCT02445469 -
Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes
|
N/A | |
Recruiting |
NCT05222386 -
Community Outreach for Palliative Engagement -- Parkinson Disease
|
N/A |